In short, through network pharmacology and enrichment analysis, we screened five components, methyl cinnamate, propyl cinnamate, ( +)-procyanidin B2, procyanidin B1, and myristicin as the brain synapse-targeting active substances of cinnamon, and identified GABRA1, GABRB2, GABRA5 and GABRG2 as core therapeutic targets of cinnamon against Alzheimer’s disease-related GABAergic synaptic dysfunction. Here, GABRA5 is linked to early-onset autosomal dominant Alzheimer disease.